Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

Contractors owed 'nearly £60k' in pre-reg grants from Capita

Contractors in the Avicenna pharmacy group are owed around £59,000 in grant payments for hosting pre-registration trainees, its CEO has said.

These pharmacy owners are still waiting for £35,000-worth of payments relating to a total of eight pre-reg pharmacists they took on last year, plus £24,000 for three trainees recruited this year, Salim Jetha told C+D last week (March 2).

Contractors can apply for an annual grant from NHS England for up to £18,440 for every pre-reg taken on, to help cover the costs of training. Service supplier Capita took on responsibility for delivering NHS England’s primary care support services in September 2015, including overseeing the pre-reg training grants.

Mr Jetha added that his own pharmacy – Lewis Grove Pharmacy in Lewisham – is also owed thousands of pounds, and he has not received a pre-reg payment since last September.

The CEO of a London local pharmaceutical committee (LPC), who did not want to be named, said several contractors in his area had raised similar concerns about overdue pre-reg payments, with one reported to be waiting for £24,000.

“The issue has been gradually escalating since October last year,” the LPC CEO said. The ongoing issue is putting contractors in a “very difficult position”, as they are already facing cash flow problems due to the funding cuts across England, they stressed.

One commenter on the C+D website described Capita’s payments process as a “scandal”.

Capita responds

In response to the complaints, a Capita spokesperson told C+D yesterday (March 7) that the company is aware of “some isolated issues” and that all claims that meet “the required checks” have been backdated, as will any further claims.

The spokesperson claimed one of the "key improvements" under Capita has been the introduction of a "centralised" process for dealing with primary care.

The old system was localised, meaning grant claims “came in from various sources on an ad hoc and irregular basis”, the spokesperson added.

The LPC CEO said they had managed to make “some progress” on behalf of “at least two or three” contractors, by liaising with both NHS England and Capita.

However, Mr Jetha's most recent attempt to contact Capita – an email sent at the end of February – bounced back because the inbox was full, he said.

“It’s crazy – they’re not even looking at their emails. They don’t give you a phone number. Who are you supposed to talk to? If the email inbox is full, what are you supposed to do?”

Mr Jetha said in his experience, the process for claiming pre-reg grants has become worse since Capita took over.

“[Under the old system,] the first payment normally came one or two months [after the grant application was submitted], which is understandable, and then it came monthly. Now, it comes abruptly. They’re not systematic,” he stressed.

NHS England was not available for comment.

Are you experiencing delays to pre-reg training grants?

Related Content

Topics

         
Pharmacist Manager
Barnsley
£30 per hour

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD008632

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel